Wulf O. Bocher
Biberach An Der Riss, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Selective SIK2/SIK3 inhibition reprograms pro- and antiinflammatory pathways in myeloid cells, improving autoimmune disease outcomes.
Journal: JCI insight
Published: July 03, 2025
Fecal MicroRNAs Show Promise as Noninvasive Crohn's Disease Biomarkers.
Journal: Crohn's & colitis 360
Published: November 20, 2019
Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study.
Journal: Journal of Crohn's & colitis
Published: July 23, 2018
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Journal: The lancet. Gastroenterology & hepatology
Published: May 25, 2018
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Journal: Lancet (London, England)
Published: July 26, 2016
Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.
Journal: European journal of gastroenterology & hepatology
Published: May 04, 2016
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
Journal: Annals of hepatology
Published: April 07, 2016
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection.
Journal: PloS one
Published: June 19, 2015
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.
Journal: Antimicrobial agents and chemotherapy
Published: December 17, 2014
Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients.
Journal: The Journal of pharmacology and experimental therapeutics
Published: September 11, 2014
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: July 30, 2014
SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.
Journal: Antimicrobial agents and chemotherapy
Published: April 09, 2014
Last Updated: 09/26/2026